Abstract
Fundamental and clinical studies on cefuzonam (CZON, L-105), a new oxime type cephalosporin, were performed and the results obtained are summarized below:
1. Concentrations of CZON were determined in serum, internal genital organs and retroperitoneal fluid after a single intravenous administration of 1 g dose.
The peripheral serum level of CZON was 74.0 μg/ml at 15 minutes after the administration. A sufficient transfer of CZON into internal genital organs and retroperitoneal fluid was demonstrated.
2. In clinical trial, CZON was given to 11 cases with obstetrical and gynecological infections.
Efficacies were evaluated as good in 9 cases and poor in 2 cases.
No side effects were observed in any of the cases treated with CZON.
In laboratory examinations, transient elevation of serum GOT, GPT and alkaline phosphatase was noted in 1 case.
